2
|
Bernasconi-Elias P, Hu T, Jenkins D, Firestone B, Gans S, Kurth E, Capodieci P, Deplazes-Lauber J, Petropoulos K, Thiel P, Ponsel D, Hee Choi S, LeMotte P, London A, Goetcshkes M, Nolin E, Jones MD, Slocum K, Kluk MJ, Weinstock DM, Christodoulou A, Weinberg O, Jaehrling J, Ettenberg SA, Buckler A, Blacklow SC, Aster JC, Fryer CJ. Characterization of activating mutations of NOTCH3 in T-cell acute lymphoblastic leukemia and anti-leukemic activity of NOTCH3 inhibitory antibodies. Oncogene 2016; 35:6077-6086. [PMID: 27157619 PMCID: PMC5102827 DOI: 10.1038/onc.2016.133] [Citation(s) in RCA: 60] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/19/2016] [Accepted: 03/07/2016] [Indexed: 01/07/2023]
Abstract
Notch receptors have been implicated as oncogenic drivers in several cancers, the most notable example being NOTCH1 in T-cell acute lymphoblastic leukemia (T-ALL). To characterize the role of activated NOTCH3 in cancer, we generated an antibody that detects the neo-epitope created upon gamma-secretase cleavage of NOTCH3 to release its intracellular domain (ICD3), and sequenced the negative regulatory region (NRR) and PEST domain coding regions of NOTCH3 in a panel of cell lines. We also characterize NOTCH3 tumor-associated mutations that result in activation of signaling and report new inhibitory antibodies. We determined the structural basis for receptor inhibition by obtaining the first co-crystal structure of a NOTCH3 antibody with the NRR protein and defined two distinct epitopes for NRR antibodies. The antibodies exhibit potent anti-leukemic activity in cell lines and tumor xenografts harboring NOTCH3 activating mutations. Screening of primary T-ALL samples reveals that two of 40 tumors examined show active NOTCH3 signaling. We also identified evidence of NOTCH3 activation in 12 of 24 patient-derived orthotopic xenograft models, two of which exhibit activation of NOTCH3 without activation of NOTCH1. Our studies provide additional insights into NOTCH3 activation and offer a path forward for identification of cancers that are likely to respond to therapy with NOTCH3 selective inhibitory antibodies.
Collapse
Affiliation(s)
- P Bernasconi-Elias
- Developmental and Molecular Pathways, Novartis Institutes for Biomedical Research, Cambridge, MA, USA
| | - T Hu
- Center for Proteomic Chemistry, Novartis Institutes for Biomedical Research, Cambridge, MA, USA
| | - D Jenkins
- Department of Oncology, Novartis Institutes for Biomedical Research, Cambridge, MA, USA
| | - B Firestone
- Department of Oncology, Novartis Institutes for Biomedical Research, Cambridge, MA, USA
| | - S Gans
- Developmental and Molecular Pathways, Novartis Institutes for Biomedical Research, Cambridge, MA, USA
| | - E Kurth
- Department of Oncology, Novartis Institutes for Biomedical Research, Cambridge, MA, USA
| | - P Capodieci
- Developmental and Molecular Pathways, Novartis Institutes for Biomedical Research, Cambridge, MA, USA
| | - J Deplazes-Lauber
- Discovery Alliances and Technologies, MorphoSys AG, Martinsried, Germany
| | - K Petropoulos
- Discovery Alliances and Technologies, MorphoSys AG, Martinsried, Germany
| | - P Thiel
- Discovery Alliances and Technologies, MorphoSys AG, Martinsried, Germany
| | - D Ponsel
- Discovery Alliances and Technologies, MorphoSys AG, Martinsried, Germany
| | - S Hee Choi
- Department of Cancer Biology, Dana Farber Cancer Institute, Boston, MA, USA.,Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA
| | - P LeMotte
- Department of Biologics, Novartis Institutes for Biomedical Research, Cambridge, MA, USA
| | - A London
- Department of Biologics, Novartis Institutes for Biomedical Research, Cambridge, MA, USA
| | - M Goetcshkes
- Developmental and Molecular Pathways, Novartis Institutes for Biomedical Research, Cambridge, MA, USA
| | - E Nolin
- Developmental and Molecular Pathways, Novartis Institutes for Biomedical Research, Cambridge, MA, USA
| | - M D Jones
- Department of Oncology, Novartis Institutes for Biomedical Research, Cambridge, MA, USA
| | - K Slocum
- Department of Oncology, Novartis Institutes for Biomedical Research, Cambridge, MA, USA
| | - M J Kluk
- Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA
| | - D M Weinstock
- Department of Cancer Biology, Dana Farber Cancer Institute, Boston, MA, USA
| | - A Christodoulou
- Department of Cancer Biology, Dana Farber Cancer Institute, Boston, MA, USA
| | - O Weinberg
- Pathology Children Hospital Boston, Boston, MA, USA
| | - J Jaehrling
- Discovery Alliances and Technologies, MorphoSys AG, Martinsried, Germany
| | - S A Ettenberg
- Department of Oncology, Novartis Institutes for Biomedical Research, Cambridge, MA, USA
| | - A Buckler
- Developmental and Molecular Pathways, Novartis Institutes for Biomedical Research, Cambridge, MA, USA
| | - S C Blacklow
- Department of Cancer Biology, Dana Farber Cancer Institute, Boston, MA, USA.,Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA.,Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA
| | - J C Aster
- Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA.,Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA
| | - C J Fryer
- Developmental and Molecular Pathways, Novartis Institutes for Biomedical Research, Cambridge, MA, USA
| |
Collapse
|
3
|
Misiakos E, Agrogiannis G, Patapis P, Dontas I, Petropoulos K, Machairas N, Giamarellos-Bourboulis” E, Liakakos T, Machairas A. Expression of Tissue IGF 1, TGFß and EGFR in the Sequential Steps of Intestinal Adaptation in a Rat Model of Short Bowel Syndrome. Acta Chir Belg 2016. [DOI: 10.1080/00015458.2013.11680898] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Affiliation(s)
- E.P. Misiakos
- 3rd Department of Surgery,University of Athens School of Medicine,Attikon University Hospital, Athens, Greece
| | - G. Agrogiannis
- 1st Department of Pathology,University of Athens School of Medicine, Athens, Greece
| | - P. Patapis
- 3rd Department of Surgery,University of Athens School of Medicine,Attikon University Hospital, Athens, Greece
| | - I. Dontas
- 3rd Department of Surgery,University of Athens School of Medicine,Attikon University Hospital, Athens, Greece
| | - K. Petropoulos
- Laboratory of Experimental Surgery & Surgical Research, University of Athens School of Medicine, Athens, Greece
| | - N. Machairas
- 3rd Department of Surgery,University of Athens School of Medicine,Attikon University Hospital, Athens, Greece
| | | | - T. Liakakos
- 3rd Department of Surgery,University of Athens School of Medicine,Attikon University Hospital, Athens, Greece
| | - A. Machairas
- 3rd Department of Surgery,University of Athens School of Medicine,Attikon University Hospital, Athens, Greece
| |
Collapse
|
5
|
Misiakos EP, Agrogiannis G, Patapis P, Dontas I, Petropoulos K, Machairas N, Giamarellos-Bourboulis E, Liakakos T, Machairas A. Expression of tissue IGF 1, TGFbeta and EGFR in the sequential steps of intestinal adaptation in a rat model of short bowel syndrome. Acta Chir Belg 2013; 113:129-138. [PMID: 23741932] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/02/2023]
Abstract
BACKGROUND The long-term morphological changes and the expression of tissue growth factors IGF 1, TGFbeta and EGFR in the gut mucosa, during the process of intestinal adaptation were examined. METHODS Four groups of rats were used: a. Sham rats (n = 10) underwent bowel transection and reanastomosis, b. SBS rats underwent an 80% small bowel resection: group A rats (n = 10) were sacrificed 15 days after surgery, group B (n = 10), 30 days after surgery, and group C (n = 10), 60 days after surgery. Morphological small bowel parameters (villus height, lumen diameter and others) of adaptation were examined sequentially. Tissue samples were studied immunohistochemically for the detection of IGF 1, TGFbeta, and EGFR. RESULTS There was a significant increase in all morphological parameters at day 15, in the intestinal samples; a further increase followed at day 30 and day 60 (p < 0.0001). Accordingly, an increase in the expression of IGF 1, TGFbeta and EGFR was noted at day 15 (p < 0.05), and at day 30 (NS). CONCLUSION Intestinal adaptation is an ongoing process lasting more than 2 months after massive small bowel resection. Peptide growth factors are expressed in the intestine continuously during this period, but the first two weeks are the most critical for the mucosal growth.
Collapse
Affiliation(s)
- E P Misiakos
- 3rd Department of Surgery, University of Athens School of Medicine, Attikon University Hospital, Athens, Greece.
| | | | | | | | | | | | | | | | | |
Collapse
|
6
|
Suleiman SH, Salim OEH, Yousif DO, Eltahir MA, Elzaki K, Ibrahim SZ, Ahmed KM, Mudawi HM, Vini L, Silyvridou A, Kakana C, Janinis J, Diamantidou E, Navrozidou C, Boulogianni G, Hourmouzi D, Kopanakis K, Macheras A, Charalabopoulos A, Bistarakis D, Xylardistos P, Shizas D, Petropoulos K, Bakopoulos A, Liakakos T, Oikonomopoulos N, Martikos G, Patapis P, Misiakos E, Tsapralis D, Azas A, Charalobopoulos A, Liakakos L, Millo P, Allieta R, Nardi M, Brachet Contul R, Scozzari G, Alexandrou I, Lainakis N, Efstathiou E, Demetriadis D, Dolatzas T, Antypas S, Parini U, Persico F, Loffredo A, Lale Murix E, Fabozzi M, Roveroni M, Usai A, Da Broi J, Nardi MJ, Roustanis E, Benetatos N, Pappas-Gogos G, Tsimogiannis KE, Tsimoyiannis EC, Pramateftakis MG, Mantzoros I, Kanellos I, Demetriades H, Angelopoulos S, Despoudi K, Lazarides H, Tsachalis T, Sapidis N, Gouvas N, Tsiaoussis J, Pechlivanides G, Zervakis N, Xynos E. Abstracts Colorectal Games, Rethymnom, Crete, Greece, May 2008. Tech Coloproctol 2008. [DOI: 10.1007/s10151-008-0432-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|